AI In Drug Development: Avoid The ‘Flashiness,’ And Simply Ask ‘Does It Fit?’ – US FDA’s ElZarrad

 
• By Kate Rawson
  
artificial intelligence
ElZarrad said the FDA may have to think of new approaches for AI transparency. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from AI

More from Advanced Technologies